MediWound Statistics
Total Valuation
MediWound has a market cap or net worth of $209.02 million. The enterprise value is $177.18 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, before market open.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediWound has 10.81 million shares outstanding. The number of shares has increased by 12.21% in one year.
| Current Share Class | 10.81M |
| Shares Outstanding | 10.81M |
| Shares Change (YoY) | +12.21% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 1.75% |
| Owned by Institutions (%) | 41.87% |
| Float | 7.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.42 |
| Forward PS | 7.76 |
| PB Ratio | 6.68 |
| P/TBV Ratio | 6.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.15 |
| Quick Ratio | 1.99 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.72 |
Financial Efficiency
Return on equity (ROE) is -77.92% and return on invested capital (ROIC) is -38.77%.
| Return on Equity (ROE) | -77.92% |
| Return on Assets (ROA) | -19.87% |
| Return on Invested Capital (ROIC) | -38.77% |
| Return on Capital Employed (ROCE) | -44.29% |
| Revenue Per Employee | $173,090 |
| Profits Per Employee | -$191,180 |
| Employee Count | 111 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 4.77 |
Taxes
In the past 12 months, MediWound has paid $42,000 in taxes.
| Income Tax | 42,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.29% in the last 52 weeks. The beta is 0.32, so MediWound's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +24.29% |
| 50-Day Moving Average | 19.65 |
| 200-Day Moving Average | 17.98 |
| Relative Strength Index (RSI) | 43.87 |
| Average Volume (20 Days) | 48,855 |
Short Selling Information
| Short Interest | 916,741 |
| Short Previous Month | 954,044 |
| Short % of Shares Out | 9.96% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.88 |
Income Statement
In the last 12 months, MediWound had revenue of $19.21 million and -$21.22 million in losses. Loss per share was -$2.06.
| Revenue | 19.21M |
| Gross Profit | 2.77M |
| Operating Income | -20.89M |
| Pretax Income | -12.55M |
| Net Income | -21.22M |
| EBITDA | -20.08M |
| EBIT | -20.89M |
| Loss Per Share | -$2.06 |
Full Income StatementBalance Sheet
The company has $38.27 million in cash and $6.42 million in debt, giving a net cash position of $31.84 million or $2.95 per share.
| Cash & Cash Equivalents | 38.27M |
| Total Debt | 6.42M |
| Net Cash | 31.84M |
| Net Cash Per Share | $2.95 |
| Equity (Book Value) | 31.27M |
| Book Value Per Share | 2.90 |
| Working Capital | 25.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.13 million and capital expenditures -$5.97 million, giving a free cash flow of -$19.10 million.
| Operating Cash Flow | -13.13M |
| Capital Expenditures | -5.97M |
| Free Cash Flow | -19.10M |
| FCF Per Share | -$1.77 |
Full Cash Flow StatementMargins
Gross margin is 14.39%, with operating and profit margins of -108.73% and -110.45%.
| Gross Margin | 14.39% |
| Operating Margin | -108.73% |
| Pretax Margin | -110.23% |
| Profit Margin | -110.45% |
| EBITDA Margin | -104.52% |
| EBIT Margin | -108.73% |
| FCF Margin | n/a |
Dividends & Yields
MediWound does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.21% |
| Shareholder Yield | -12.21% |
| Earnings Yield | -10.15% |
| FCF Yield | -9.14% |
Analyst Forecast
The average price target for MediWound is $35.00, which is 80.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.00 |
| Price Target Difference | 80.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 41.78% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 20, 2022. It was a reverse split with a ratio of 0.1428571:1.
| Last Split Date | Dec 20, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.1428571:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
